- Policy
- Korean researchers develop 1st new substance for Alzheimer's
- by Lee, Hye-Kyung Nov 9, 2023 05:43am
- A Korean research team has developed a new substance (ALT001) that promotes mitophagy, and the recycling of damaged mitochondria, and presented a new door to treating Alzheimer's type dementia. The Korea Health Industry Development Institute (President: Soon-Do Cho) announced that a joint research team that consists of Jin-ho Yoon (College of
- Company
- Prescriptions of HCV market leader Mavyret halves in 1 yr
- by Kim, Jin-Gu Nov 9, 2023 05:43am
- Outpatient prescription performance of ‘Mavyret,’ the No. 1 product in the hepatitis C treatment market, has shrunk to less than half in just 1 year. In addition to the decrease in overall market size due to the decline in hepatitis C patients, Mavyret’s newly released competitors 'Epclusa' and ‘Vosevi’ have been rapidly expanding th
- Company
- Velexbru can be prescribed at general hospitals
- by Eo, Yun-Ho Nov 9, 2023 05:43am
- Velexbru, a new drug for lymphoma, can be prescribed at general hospitals. According to related industries, Ono Pharmaceutical's BTK (Brutons Tyrosine Kinase) inhibitor Velexbru recently passed the Drug Committee of top general hospitals such as AMC and Sinchon Severance Hospital. In addition, major medical institutions, including Samsung Seo
- Policy
- Drug pricing nego start in earnest for Tagrisso·Leclaza
- by Lee, Tak-Sun Nov 9, 2023 05:43am
- With drug pricing negotiations ongoing for the reimbursement of Tagrisso (AZ, osimertinib) and Leclaza (Yuhan, lasertinib) as a first-line treatment for non-small cell lung cancer, whether the two drugs will be applied the initial treatment refund-type RSA (risk-sharing agreement system) remains a variable. Leclaza, which is being supp
- Policy
- MFDS approves P3T for talquetamab in MM patients
- by Lee, Hye-Kyung Nov 8, 2023 05:37am
- Janssen Korea received approval to initiate a Phase III trial for its first-in-class investigational bispecific antibody ‘talquetamab’ for multiple myeloma in Korea. The drug is ‘Talvey,’ which was approved by the US FDA in August. The FDA granted accelerated approval to Talvey based on its overall response rate and duration of respon
- Policy
- Daewoong starts developing XR formulation of tofacitinib
- by Lee, Tak-Sun Nov 8, 2023 05:37am
- Daewoong Pharmaceutical has begun developing a product that can rival Pfizer's oral JAK inhibitor 'Xeljanz XR 11mg'. Xeljanz XR (tofacitinib citrate) is Prizer's latest tofacitinib product approved in December 2020. Daewoong Pharmaceutical, like the original company Pfizer, is building a lineup of immediate-release and extended-release ta
- Policy
- PN injection benefit restriction suddenly halted
- by Nho, Byung Chul Nov 8, 2023 05:37am
- With the advent of the reevaluation period for selective coverage of intraarticular injections containing PN (sodium polynucleotide), health authorities are planning to adjust the patient copayment upward. Manufacturers and sellers have recently submitted opinions to HIRA, drawing attention to the future direction. The opinion is based on su
- Company
- Whether Ilaris for 10 will receive reimb gains attention
- by Eo, Yun-Ho Nov 8, 2023 05:37am
- Attention is focused on whether progress will be made on discussions for the insurance reimbursement of 'Ilaris', a treatment that is used by around ten patients in Korea. According to industry sources, reimbursement discussions for Novartis Korea’s Ilaris (canakinumab) are currently being negotiated between the government and pharmaceut
- Policy
- A draft for reevaluation of overseas drug prices
- by Lee, Tak-Sun Nov 8, 2023 05:37am
- Advantages and disadvantages depending on the re-evaluation method. The HIRA has prepared a draft plan for comparative and reevaluation of overseas drug prices and will begin collecting opinions in earnest with the pharmaceutical industry starting this month. As the HIRA plans to conduct re-evaluation sequentially starting next year, it is e
- Company
- Budesonide’s price to be raised due to increased demand
- by Chon, Seung-Hyun Nov 7, 2023 05:34am
- Health authorities are working to increase the price of asthma medications containing ‘budesonide’, which have been experiencing supply shortages. Quarterly prescriptions of budesonide, which was less than KRW 1 billion, more than tripled after the COVID-19 pandemic, intensifying the supply and demand imbalance. According to industry source
